PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma

  • Tetsuhiro KasamatsuEmail author
  • Maaya Awata
  • Rei Ishihara
  • Yuki Murakami
  • Nanami Gotoh
  • Morio Matsumoto
  • Morio Sawamura
  • Akihiko Yokohama
  • Hiroshi Handa
  • Norifumi Tsukamoto
  • Takayuki Saitoh
  • Hirokazu Murakami
Original Article


Single-nucleotide polymorphisms (SNPs) of the programmed cell death protein-1 (PDCD1), programmed cell death protein-1 ligand-1 (PDCD1LG1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA4) genes are implicated in the pathogenesis of some cancers. We investigated the role of PDCD1, PDCD1LG1, and CTLA4 SNPs in MM pathogenesis and the susceptibility to and clinical features of multiple myeloma (MM). We obtained genomic DNA from 124 patients with MM and 211 healthy controls and detected PDCD1 (rs36084323, rs41386349, and rs2227982), PDCD1LG1 (rs2297136 and rs4143815), and CTLA4 (rs733618, rs11571316, rs231775, and rs3087243) genotypes using the polymerase chain reaction–restriction fragment length polymorphism method or the TaqMan allelic discrimination real-time PCR method. The patients with MM had a significantly higher frequency of the PDCD1 GCC/GCC haplotype (rs36084323/rs41386349/rs2227982) compared with the healthy controls. PDCD1 rs2227982 CC genotype was associated significantly with a higher frequency of bone lesions. Patients with PDCD1LG1 rs2297136 TT and TC types (high-expression types) showed lower albumin level than those with CC genotype. In addition, the PDCD1LG1 rs4143815 CC and CG types (high-expression types) were associated significantly with higher frequency of patients who were treated with thalidomide and/or bortezomib. However, there was no statistical significance between CTLA4 polymorphisms and clinical variables of patients with MM. There were no significant differences between all the polymorphisms and OS. Our study indicates that the PDCD1 haplotype is associated with a susceptibility to MM. The PDCD1 rs2227982 and PDCD1LG1 rs2297136 affect the clinical features of multiple myeloma patients.


Programmed cell death protein-1 Programmed cell death protein-1 ligand-1 Multiple myeloma Polymorphism 



This work was supported by JSPS KAKENHI (Grant Number JP 16K19190).

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Gunma University Hospital (Approval #160007) and with the 1964 Declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.CrossRefGoogle Scholar
  2. 2.
    Merchionne F, Perosa F, Dammacco F. New therapies in multiple myeloma. Clin Exp Med. 2007;7(3):83–97.CrossRefGoogle Scholar
  3. 3.
    Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol. 2011;6:249–74.CrossRefGoogle Scholar
  4. 4.
    Liu H, Pan Y, Meng S, Zhang W, Zhou F. Current treatment options of T cell-associated immunotherapy in multiple myeloma. Clin Exp Med. 2017;17(4):431–9.CrossRefGoogle Scholar
  5. 5.
    Shen X, Guo Y, Yu J, Qi J, Shi W, Wu X, Ni H, Ju S. miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor. Clin Exp Med. 2016;16(3):307–16.CrossRefGoogle Scholar
  6. 6.
    Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365–9.CrossRefGoogle Scholar
  7. 7.
    Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.CrossRefGoogle Scholar
  8. 8.
    Braga WM, da Silva BR, de Carvalho AC, et al. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunol Immunother. 2014;63(11):1189–97.CrossRefGoogle Scholar
  9. 9.
    Tamura H, Ishibashi M, Yamashita T, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013;27(2):464–72.CrossRefGoogle Scholar
  10. 10.
    Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704.CrossRefGoogle Scholar
  11. 11.
    Mojtahedi Z, Mohmedi M, Rahimifar S, Erfani N, Hosseini SV, Ghaderi A. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. Gene. 2012;508(2):229–32.CrossRefGoogle Scholar
  12. 12.
    Tang W, Wang Y, Jiang H, et al. Programmed death-1 (PD-1) rs2227981 C>T polymorphism is associated with cancer susceptibility: a meta-analysis. Int J Clin Exp Med. 2015;8(12):22278–85.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Lee SY, Jung DK, Choi JE, et al. Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer. Gene. 2017;599:28–35.CrossRefGoogle Scholar
  14. 14.
    Tang W, Qiu H, Jiang H, et al. Lack of association between cytotoxic T-lymphocyte antigen 4 (CTLA-4)-1722T/C (rs733618) polymorphism and cancer risk: from a case-control study to a meta-analysis. PLoS ONE. 2014;9(4):e94039.CrossRefGoogle Scholar
  15. 15.
    Anjos S, Nguyen A, Ounissi-Benkalha H, Tessier MC, Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem. 2002;277(48):46478–86.CrossRefGoogle Scholar
  16. 16.
    Ishizaki Y, Yukaya N, Kusuhara K, et al. PD1 as a common candidate susceptibility gene of subacute sclerosing panencephalitis. Hum Genet. 2010;127(4):411–9.CrossRefGoogle Scholar
  17. 17.
    Zheng L, Li D, Wang F, et al. Association between hepatitis B viral burden in chronic infection and a functional single nucleotide polymorphism of the PDCD1 gene. J Clin Immunol. 2010;30(6):855–60.CrossRefGoogle Scholar
  18. 18.
    Perez-Garcia A, Osca G, Bosch-Vizcaya A, et al. Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription. Hum Immunol. 2013;74(9):1219–24.CrossRefGoogle Scholar
  19. 19.
    Wang W, Li F, Mao Y, et al. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet. 2013;132(6):641–8.CrossRefGoogle Scholar
  20. 20.
    Lee SY, Jung DK, Choi JE, et al. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel–cisplatin chemotherapy. Sci Rep. 2016;6:25952.CrossRefGoogle Scholar
  21. 21.
    Rosenblatt J, Glotzbecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011;34(5):409–18.CrossRefGoogle Scholar
  22. 22.
    Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286–94.CrossRefGoogle Scholar
  23. 23.
    Ishibashi M, Tamura H, Sunakawa M, et al. Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1. Cancer Immunol Res. 2016;4(9):779–88.CrossRefGoogle Scholar
  24. 24.
    Karabon L, Pawlak-Adamska E, Tomkiewicz A, et al. Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population. Pathol Oncol Res. 2012;18(2):219–26.CrossRefGoogle Scholar
  25. 25.
    Lee MY, Park CJ, Cho YU, et al. Immune checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) expression in plasma cell myeloma. Blood. 2017;130:4400.Google Scholar
  26. 26.
    Yamashita T, Tamura H, Satoh C, et al. Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage. Clin Cancer Res. 2009;15(3):770–7.CrossRefGoogle Scholar
  27. 27.
    Nagahama K, Aoki K, Nonaka K, et al. The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. Bone. 2004;35(5):1059–68.CrossRefGoogle Scholar
  28. 28.
    Dhodapkar MV, Sexton R, Das R, et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood. 2015;126(22):2475–8.CrossRefGoogle Scholar
  29. 29.
    Wang L, Wang H, Chen H, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015;6(38):41228–36.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Huang SY, Lin HH, Lin CW, et al. Soluble PD-L1: a biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget. 2016;7(38):62490–502.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Qin XY, Lu J, Li GX, et al. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Ann Hematol. 2018;97(3):485–95.CrossRefGoogle Scholar
  32. 32.
    Gorgun G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21(20):4607–18.CrossRefGoogle Scholar
  33. 33.
    Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013;62(1):39–49.CrossRefGoogle Scholar
  34. 34.
    Driscoll J, Aslam I, Malek E. Eosinophils upregulate PD-L1 and PD-L2 expression to enhance the immunosuppressive microenvironment in multiple myeloma. Blood. 2017;130:4417.Google Scholar
  35. 35.
    Gibson HM, Mishra A, Chan DV, Hake TS, Porcu P, Wong HK. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sezary syndrome. J Invest Dermatol. 2013;133(1):249–57.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Tetsuhiro Kasamatsu
    • 1
    Email author
  • Maaya Awata
    • 1
  • Rei Ishihara
    • 1
  • Yuki Murakami
    • 1
  • Nanami Gotoh
    • 1
  • Morio Matsumoto
    • 2
  • Morio Sawamura
    • 2
  • Akihiko Yokohama
    • 3
  • Hiroshi Handa
    • 4
  • Norifumi Tsukamoto
    • 5
  • Takayuki Saitoh
    • 1
  • Hirokazu Murakami
    • 1
    • 6
  1. 1.Department of Laboratory SciencesGunma University Graduate School of Health SciencesMaebashiJapan
  2. 2.Department of HematologyNational Hospital Organization Shibukawa Medical CenterShibukawaJapan
  3. 3.Blood Transfusion ServiceGunma University HospitalMaebashiJapan
  4. 4.Department of HematologyGunma UniversityMaebashiJapan
  5. 5.Oncology CenterGunma University HospitalMaebashiJapan
  6. 6.Gunma University of Health and WelfareMaebashiJapan

Personalised recommendations